During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...